Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
IRCCS Azienda Ospedaliero-Universitaria di Bologna
UMC Utrecht
Pfizer
Tempus AI
Università Cattolica di Milano
Eli Lilly and Company
ViroMissile, Inc.
Sichuan Enray Pharmaceutical Sciences Company
AstraZeneca
Tizona Therapeutics, Inc
Hospices Civils de Lyon
Georgetown University
University of California, Davis
Elephas
M.D. Anderson Cancer Center
Universidad de Granada
Var2 Pharmaceuticals
Elephas
OncoNano Medicine, Inc.
Institut de Cancérologie de Lorraine
Calico Life Sciences LLC
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
Children's Hospital of Philadelphia
Cancer Research UK
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
Vanderbilt-Ingram Cancer Center
University of California, San Francisco
Nurix Therapeutics, Inc.
A2 Biotherapeutics Inc.
University Hospital, Clermont-Ferrand
RefleXion Medical
Coherus Oncology, Inc.
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Cancer Research UK
Erasmus Medical Center
University of California, San Francisco
The New York Proton Center
University of Modena and Reggio Emilia
Simcha IL-18, Inc.
King Saud University
BlueSky Immunotherapies GmbH
Cancer Research UK
Sanguine Biosciences
Sheffield Teaching Hospitals NHS Foundation Trust
Taipei Veterans General Hospital, Taiwan
Centre Hospitalier Universitaire, Amiens